Preclinical data for potent IDO pathway inhibitor presented at AACR 2013 annual meeti

[News]

NewLink Genetics Corporation, a biopharmaceutical company primarily focused on discovering, developing and commercializing immunotherapeutic products in oncology, announced today that the company presented preclinical data for NLG919, a potent IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor, at the American Association for Cancer Research 2013 annual meeting.

More... (http://www.news-medical.net/news/20130408/Preclinical-data-for-potent-IDO-pathway-inhibitor-presented-at-AACR-2013-annual-meeting.aspx)